Maridose, a DEA licensed manufacturer specializing in cannabis-based products, announced the launch of its Contract Research Organization (CRO) group. This newly formed group is dedicated to collaborating with researchers engaged in the development of cannabis-based drugs for pre-clinical and clinical trials, as well as aiding in the commercialization process.
The company's CRO services cater to pharmaceutical and biotech firms, academic institutions, authorized cannabis companies, and other entities legally permitted to conduct research on Schedule I drugs.
Maridose's CRO services encompass a suite of offerings designed to support every phase of drug development, from initial research to final commercialization. Services include but are not limited to:
- Pre-Clinical and Clinical Trial Support: Providing expertise in the design, execution, and monitoring of pre-clinical and clinical trials for cannabis-derived pharmaceuticals.
- Regulatory Guidance: Assisting clients in navigating the complex regulatory landscape, including advice on obtaining necessary licenses for conducting research on Schedule I substances.
- Formulation Development: Collaborating with researchers to optimize drug formulations for enhanced efficacy and safety.
- Quality Control and Assurance: Implementing rigorous quality control measures to ensure compliance with industry standards and regulatory requirements.